论文部分内容阅读
目的探讨羟苯磺酸钙治疗早期糖尿病肾病(DN)的疗效及安全性。方法 50例2型糖尿病(T2DM)患者,随机分为观察组和对照组,每组25例。所有患者均进行饮食控制、降糖等基础治疗。观察组在此基础上加用羟苯磺酸钙,连续治疗12周。观察两组治疗前、治疗12周时的24 h尿白蛋白排出量(UAE)、血清内皮素(ET)、一氧化氮(NO)、糖化血红蛋白(Hb A1c)、谷丙转氨酶(ALT)、尿素氮(BUN)、肌酐(Cr)的变化。结果治疗后,观察组UAE为(27.1±13.4)mg/24 h,明显低于对照组的(83.5±20.6)mg/24 h(P<0.05);治疗后,观察组NO水平明显高于对照组,ET明显低于对照组(P<0.05)。结论羟苯磺酸钙对Ⅲ期DN具有良好的效果,该药可能通过降低血ET,增加血NO来发挥对肾脏的保护作用,值得临床推广应用。
Objective To investigate the efficacy and safety of calcium dobesilate in the treatment of early diabetic nephropathy (DN). Methods Fifty patients with type 2 diabetes mellitus (T2DM) were randomly divided into observation group and control group, with 25 cases in each group. All patients were diet control, hypoglycemic and other basic treatment. On the basis of this observation, the observation group added calcium dobesilate for 12 weeks. The levels of 24 h urinary albumin (UAE), serum ET, NO, Hb A1c, ALT, Changes of BUN and Cr. Results After treatment, the UAE in the observation group was (27.1 ± 13.4) mg / 24 h, which was significantly lower than that in the control group (83.5 ± 20.6) mg / 24 h (P <0.05). After treatment, the NO level in the observation group was significantly higher than that in the control group Group, ET was significantly lower than the control group (P <0.05). Conclusion Calcium dobesilate has a good effect on stage Ⅲ DN. This medicine may exert protective effect on the kidneys by lowering blood ET and increasing blood NO, which is worthy of clinical application.